L-Valine
|
Basic information |
| Metabolite name | L-Valine |
 | HMDB0000883 |
 |
C00183 |
 |
6287 |
| Synonyms | 2-Aminoisovaleric acid; |
| No. of studies | 79 |
|
Basic information |
| Metabolite name | L-Valine |
| HMDB0000883 |
|
C00183 |
|
6287 |
| Synonyms | 2-Aminoisovaleric acid; |
| No. of studies | 79 |
|
Relationship between L-Valine and depression (count: 79) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Thalamus | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M017 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M019 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M021 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M030 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M035 | Type1 | depressed suicide attempters group vs. control group | Plasma | Human | Down |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M071 | Type2 | CUMS + imipramine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Up |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Down |
| Study M098 | Type1 | depressed group vs. control group | Peripheral blood mononuclear cell | Human | Down |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1042 | Type1 | CUMS + MCAO group vs. MCAO group | Faece | Sprague-Dawley rat | Down |
| Study M1056 | Type2 | maternal separation + beraprost group vs. maternal separation group | Serum | Sprague-Dawley rat | Down |
| Study M1057 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M1074 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Up |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6N mouse | Down |
| Study M111 | Type3 | WT-Scop group vs. WT-Veh group | Plasma | C57BL/6 mouse | Down |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M132 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M132 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M133 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M133 | Type2 | CUMS + XY-A group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M137 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M137 | Type2 | CUMS + hypericin group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M457 | Type2 | CUMS + D6 doses of PBR group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M463 | Type3 | DG group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M510 | Type1 | LQS group vs. control group | Serum | Human | Up |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M553 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M592 | Type1 | CUMS group vs. control group, NMR | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M610 | Type1 | CUMS group vs. control group | Heart | Sprague-Dawley rat | Up |
| Study M611 | Type1 | LPS group vs. control group | Heart | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M635 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M635 | Type2 | depression group, after vs. before Xiaoyaosan treatment | Plasma | Human | Up |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type2 | CUMS + low dose of Chaihu group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Chaihu-Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Serum | C57BL/6J mouse | Down |
| Study M750 | Type2 | CUMS + CCFM1025 group vs. CUMS group | Faece | C57BL/6 mouse | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M790 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M791 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Cecum | Sprague-Dawley rat | Up |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M830 | Type1 | corticosterone group vs. control group | Brain | Swiss mouse | Down |
| Study M830 | Type2 | corticosterone + acupoint catgut embedding group vs. corticosterone group | Brain | Swiss mouse | Up |
| Study M847 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M858 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type2 | ovariectomy + CUMS + Xiang-Su volatile oil group vs. ovariectomy + CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M874 | Type1 | ovariectomy group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M874 | Type2 | ovariectomy + Panax ginseng group vs. ovariectomy group | Urine | Sprague-Dawley rat | Down |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M924 | Type2 | CUMS + aerobic exercise group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M943 | Type1 | CUMS group vs. control group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | ICR mouse | Down |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Down |
| Study M947 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M950 | Type2 | probiotic group vs. placebo group | Faece | Human | Up |
| Study M956 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |